Immunitas Therapeutics
5 known investors
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
BiotechDigital HealthMedical Devices
Investors · 5
In the news
- Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meetingprnewswire.com · 2023
- Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseasesprnewswire.com · 2021
- Immunitas Therapeutics - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Immunitas Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform | AP Newsapnews.com · 2019
- Immunitas Therapeutics Raises $39M in Series A Funding - FinSMEsfinsmes.com · 2019